2026年2月19日,Beeringer Ingelheim India和NIPER Raebaleli签署了一份谅解备忘录,以推进印度的药物研究和教育。 Boehringer Ingelheim India and NIPER Raebareli signed an MoU on Feb. 19, 2026, to advance pharmaceutical research and education in India.

2026年2月19日, Boehringer Ingelheim India 和NIPER Raebaleli在新德里签署了一份谅解备忘录,以促进药物教育和研究。 On February 19, 2026, Boehringer Ingelheim India and NIPER Raebareli signed an MoU in New Delhi to boost pharmaceutical education and research. 该伙伴关系旨在推进药物运载系统、制药技术和学术交流,由Boehringer Ingelheim提供进入其开放科学门户的机会。 The partnership aims to advance drug delivery systems, pharmaceutical technologies, and academic exchange, with Boehringer Ingelheim providing access to its open science portal. 联合倡议包括专题讨论会、短期课程和学术计划,支持印度转向创新驱动的制药部门,以及维基特·巴拉特2047愿景。 Joint initiatives include symposia, short courses, and scholar programs, supporting India’s shift toward an innovation-driven pharmaceutical sector and the Viksit Bharat 2047 vision.